SOLID BIOSCIENCES INC (SLDB)
Health Care · Gene therapy · NASDAQ
A gene therapy company advancing a pipeline of treatments for rare neuromuscular and cardiac diseases including Duchenne muscular dystrophy, Friedreich's ataxia, and cardiomyopathy.
What SOLID BIOSCIENCES INC does
Solid Biosciences is a life sciences company focused on developing gene therapy candidates for rare neuromuscular and cardiac genetic diseases. The company is advancing a diverse pipeline including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich's ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for TNNT2-mediated dilated cardiomyopathy. The company integrates internal capabilities including a vector core, validated animal models, optimized expression cassettes, novel capsids, and regulatory expertise to develop high-value genetic medicines for patients with neuromuscular and cardiac diseases.
Themes: ["Gene therapy / genetic medicines","Rare neuromuscular diseases","Genetic cardiac diseases","Duchenne muscular dystrophy","Orphan drugs"]
Fundamentals
- Price$11.14 as of 2026-07-09 close
- Market cap$1.1B as of 2026-07-10
- 1-year return+109.9% as of 2026-07-09 close
- Net margin-588.3% as of 2026-07-10
- ROE-74.5% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta2.38 as of 2026-07-10
Key risks (from latest filing)
["Clinical trial and regulatory risk: advancement of pipeline candidates depends on successful completion of preclinical studies and clinical trials with uncertain timing and outcomes, and ability to obtain FDA and foreign regulatory approvals","Manufacturing and scale-up risk: company faces capacity constraints and uncertainty around scalability and commercial viability of manufacturing methods and processes for gene therapies","Financial and going concern risk: company is unprofitable with significant ongoing losses and faces uncertainty around access to sufficient capital to fund development activities and continue operations"]
Competitors & peers
- Sarepta Therapeutics
- Pfizer (gene therapy programs)
- Roche/Spark Therapeutics
- Regenxbio
- Audentes Therapeutics
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.